The 9 most recent market catalysts affecting $MDXH, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 21, 2026
Corporate Catalyst
Bearish
Impact 55
BTIG Maintains Buy on MDxHealth, Lowers Price Target to $2
BTIG analyst Mark Massaro has revised the price target for MDxHealth (MDXH) from $4 to $2, while keeping a 'Buy' rating. This action indicates a re-evaluation of the company's near…
Aug 14, 2026
Corporate Catalyst
Bearish
Impact 55
Lake Street Maintains Buy on MDxHealth, Lowers Price Target to $3
Lake Street analyst Thomas Flaten maintained a 'Buy' rating on MDxHealth (MDXH) but lowered the price target from $5 to $3. This action signals that while the analyst still believe…
Aug 14, 2026
Corporate Catalyst
Bearish
Impact 85
MDxHealth Says Well-Positioned to 'Return to Positive EBITDA'
MDxHealth (MDXH) reported a mixed second quarter, with an EPS miss but a revenue beat, which is often overlooked by the market if future prospects are strong. The key catalyst here…
Aug 14, 2026
Corporate Catalyst
Bullish
Impact 65
12 Health Care Stocks Moving In Friday's Intraday Session
This filing is a compilation of intraday stock movements for various healthcare companies, with the primary catalyst being recent quarterly earnings reports. The significant percen…
Aug 14, 2026
Macro/Central Bank
Bearish
Impact 75
US Stocks Mixed; Retail Sales Fall In July
The filing highlights a mixed day for US equities, with the Nasdaq and S&P 500 showing modest gains while the Dow dipped. The most significant macro event is the unexpected 0.6% de…
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 85
MDxHealth shares are trading higher after the company reported better-than-expected Q2 sales results and affirmed its FY26 sales guidance above estimates.
This headline is a significant corporate catalyst, directly impacting MDxHealth's stock price positively. The better-than-expected Q2 sales demonstrate strong current performance, …
Aug 13, 2026
Corporate Catalyst
Bearish
Impact 65
MDxHealth Affirms FY2026 Sales Guidance of $110.000M-$115.000M vs $98.814M Est
MDxHealth (MDXH) filed an 8-K to affirm its fiscal year 2026 sales guidance, keeping it at $110 million to $115 million. This is significant because the reaffirmed guidance is nota…
Aug 13, 2026
Corporate Catalyst
Bearish
Impact 85
MDxHealth Q2 EPS $(0.18) Misses $(0.16) Estimate, Sales $27.200M Beat $25.884M Estimate
MDxHealth's Q2 earnings report shows a mixed financial performance. The company missed analyst consensus on EPS, reporting a loss of $(0.18) per share, which is a 20% increase in l…
Jul 24, 2026
Corporate Catalyst
Neutral
Impact 75
MDxhealth Receives Nasdaq Noncompliance Notice
MDxhealth has received a second non-compliance notice from Nasdaq, this time for failing to meet the minimum market value requirement, compounding its existing issue with the minim…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.